or Try an Advanced Search...

    Technical Analysis for EOLS - Evolus, Inc.

    Grade Last Price % Change Price Change
    D 11.43 -0.26% -0.03
    EOLS closed down 0.26 percent on Friday, April 26, 2024, on 1.36 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 7
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical EOLS trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Hammer Candlestick Bullish -0.26%
    Down 3 Days in a Row Weakness -0.26%
    Gapped Down Weakness -0.26%
    Oversold Stochastic Weakness -0.26%
    Oversold Stochastic Weakness -0.61%
    180 Bearish Setup Bearish Swing Setup -2.31%
    Older End-of-Day Signals for EOLS ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 19 hours ago
    Up 1% about 19 hours ago
    Possible NR7 about 19 hours ago
    Hammer Candlestick Entry about 23 hours ago
    Rose Above Previous Day's High about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    EOLS Chart by TradingView
    Basic chart:

    Profile

    Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Medicine Clinical Medicine Toxins Plastic Surgery Botulinum Toxin Botulism Aesthetic Medicine Neurotoxins

    Is EOLS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 23 Evolus to Report First Quarter Financial Results on May 7, 2024
    Apr 21 11 Best Low Price Pharma Stocks To Invest In
    Apr 17 Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®
    Apr 12 Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Apr 6 Evolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the company
    Mar 26 Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    Mar 20 Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028
    Mar 17 Survey finds GLP-1 users more inclined to get aesthetic procedures
    Mar 14 10 Stocks George Soros and Insiders Are Crazy About
    Mar 13 Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?
    See more EOLS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.4325
    52 Week Low 7.075
    Average Volume 585,456
    200-Day Moving Average 10.59
    50-Day Moving Average 13.39
    20-Day Moving Average 12.42
    10-Day Moving Average 11.65
    Average True Range 0.43
    RSI (14) 24.24
    ADX 31.4
    +DI 14.62
    -DI 32.77
    Chandelier Exit (Long, 3 ATRs) 13.06
    Chandelier Exit (Short, 3 ATRs) 12.37
    Upper Bollinger Bands 14.14
    Lower Bollinger Band 10.70
    Percent B (%b) 0.21
    BandWidth 27.68
    MACD Line -0.59
    MACD Signal Line -0.51
    MACD Histogram -0.0734
    Fundamentals Value
    Market Cap 660.2 Million
    Num Shares 57.8 Million
    EPS -1.12
    Price-to-Earnings (P/E) Ratio -10.21
    Price-to-Sales 4.28
    Price-to-Book 25.65
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.91
    Resistance 3 (R3) 11.92 11.78 11.83
    Resistance 2 (R2) 11.78 11.65 11.77 11.80
    Resistance 1 (R1) 11.60 11.58 11.53 11.59 11.78
    Pivot Point 11.46 11.46 11.42 11.45 11.46
    Support 1 (S1) 11.28 11.33 11.21 11.27 11.08
    Support 2 (S2) 11.14 11.26 11.13 11.06
    Support 3 (S3) 10.96 11.14 11.03
    Support 4 (S4) 10.95